A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer

References

• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017 Oct 19;171(3):540–556.e25.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013 May;49(8):1889–1897.
   PubMed Web of Science ®Google Scholar
• Warrick JI, Sjödahl G, Kaag M, et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol. 2019 Jan;75(1):18–22.
   PubMed Web of Science ®Google Scholar
• Church SE, Galon J. Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity. 2015 Oct 20;43(4):631–633.
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001 Oct;1(1):46–54.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Mouw KW, Gibb EA, et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol. 2019 Jul;76(1):59–68.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10;25(2):152–165.
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020 Apr;77(4):420–433.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol. 2009 Dec 21; 15(47):5898–5906.
   PubMed Web of Science ®Google Scholar
• Park JH, Richards CH, McMillan DC, et al. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014 Mar;25(3):644–651.
   PubMed Web of Science ®Google Scholar
• Choi W, Ochoa A, McConkey DJ, et al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol. 2017 Sep;72(3):354–365.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018 Apr 17;48(4):812–830.e14.
   PubMed Web of Science ®Google Scholar
• Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the international tumor budding consensus conference (ITBCC) 2016. Mod Pathol. 2017 Sep;30(9):1299–1311.
   PubMed Web of Science ®Google Scholar
• van Wyk HC, Roseweir A, Alexander P, et al. The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann Surg Oncol. 2019 Dec;26(13):4397–4404.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 May;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015 Dec 23;1(6):417–425.
   PubMed Web of Science ®Google Scholar
• Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-Esso-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014 May;40(5):584–591.
   PubMed Web of Science ®Google Scholar
• Zhu S, Yu W, Yang X, et al. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol. 2020;10:102.
   PubMed Web of Science ®Google Scholar
• Lorenzo Soriano L, Ordaz Jurado G, Pontones Moreno JL, et al. Tumor budding: prognostic value in muscle-invasive bladder cancer. Urology. 2019;130:93–98.
   PubMed Web of Science ®Google Scholar
• Brieu N, Gavriel CG, Nearchou IP, et al. Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis. Sci Rep. 2019 Mar 26;9(1):5174.
   PubMedGoogle Scholar
• Bircan S, Candir O, Kapucuoglu N. The effect of tumor invasion patterns on pathologic stage of bladder urothelial carcinomas. Pathol Oncol Res. 2005;11(2):87–91.
   PubMed Web of Science ®Google Scholar
• Ueno H, Jones AM, Wilkinson KH, et al. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004 Apr;53(4):581–586.
   PubMed Web of Science ®Google Scholar
• Teo MY, Mota JM, Whiting KA, et al. Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma. Eur Urol. 2020 Dec;78(6):907–915.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• Casadei C, Dizman N, Schepisi G, et al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol. 2019;11:1758835919890285.
   Web of Science ®Google Scholar
• Wei L, Delin Z, Kefei Y, et al. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology. 2020;9(1):1672495.
   PubMed Web of Science ®Google Scholar
• de Martino M, Zhuang D, Klatte T, et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol Ther. 2014 Sep;15(9):1239–1247.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859–866.
   PubMed Web of Science ®Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017 Oct;72(4):544–554.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015 Dec;68(6):959–967.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(†): under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020 Feb;77(2):223–250.
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Etzerodt A, Ulhøi BP, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012 Nov 15;131(10):2320–2331.
   PubMed Web of Science ®Google Scholar
• Xue Y, Tong L, LiuAnwei Liu F, et al. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol Rep. 2019 Aug;42(2):581–594.
   PubMed Web of Science ®Google Scholar
• Pico de Coaña Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015 Aug;21(8):482–491.
   PubMed Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004 Mar;45(3):292–296.
   PubMed Web of Science ®Google Scholar